Private equity

PAG buys Chinese biotech firm as SOE reform gathers pace

This acquisition will be the largest private equity investment in China’s biotechnology industry to date.

Alison Tudor-Ackroyd

September 05, 2019

Asia-focused private equity firm PAG said on Thursday that it has agreed to acquire a controlling interest in Hisun BioRay Bio-pharmaceutical, another example of state-owned enterprise reform in China.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

North Asia
M&A

#private equity
#pag
#acquisitions
#hisun bioray